Lipid-chitosan hybrid nanoparticles for controlled delivery of cisplatin

Drug Deliv. 2019 Dec;26(1):765-772. doi: 10.1080/10717544.2019.1642420.

Abstract

Lipid-polymer hybrid nanoparticles (LPHNP) are delivery systems for controlled drug delivery at tumor sites. The superior biocompatible properties of lipids and structural advantages of polymers can be obtained using this system for controlled drug delivery. In this study, cisplatin-loaded lipid-chitosan hybrid nanoparticles were formulated by the single step ionic gelation method based on ionic interaction of positively charged chitosan and negatively charged lipid. Formulations with various chitosan to lipid ratios were investigated to obtain the optimal particle size, encapsulation efficiency, and controlled release pattern. Transmission electron microscope and dynamic light scattering analysis demonstrated a size range of 181-245 nm and a zeta potential range of 20-30 mV. The stability of the formulation was demonstrated by thermal studies. Cytotoxicity and cellular interaction of cisplatin-loaded LPHNP were investigated using in vitro cell-based assays using the A2780 ovarian carcinoma cell line. The pharmacokinetics study in rabbits supported a controlled delivery of cisplatin with enhanced mean residence time and half-life. These studies suggest that cisplatin loaded LPHNP have promise as a platform for controlled delivery of cisplatin in cancer therapy.

Keywords: Cisplatin; chitosan; controlled release; lipid-polymer hybrid nanoparticles; ovarian cancer; pharmacokinetics.

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / pharmacokinetics
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Chitosan / chemistry
  • Cisplatin / administration & dosage*
  • Cisplatin / pharmacokinetics
  • Cisplatin / pharmacology
  • Delayed-Action Preparations
  • Drug Carriers / chemistry*
  • Drug Carriers / pharmacokinetics
  • Drug Delivery Systems
  • Female
  • Lipids / chemistry
  • Nanoparticles / chemistry*
  • Nanoparticles / ultrastructure
  • Ovarian Neoplasms / drug therapy
  • Particle Size
  • Polymers / administration & dosage
  • Polymers / chemistry
  • Polymers / pharmacokinetics
  • Rabbits

Substances

  • Antineoplastic Agents
  • Delayed-Action Preparations
  • Drug Carriers
  • Lipids
  • Polymers
  • Chitosan
  • Cisplatin

Grants and funding

The authors acknowledge the International Research Support Initiative Program (IRSIP) of the Higher Education Commission of Pakistan for the travel grant to Northeastern University, Boston, USA. The authors also acknowledge support by center of Pharmaceutical Biotechnology and Nanomedicines, Northeastern University, Boston, USA.